Results 221 to 230 of about 2,569,145 (337)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. [PDF]

open access: yesPLoS One, 2017
Ramsey D   +25 more
europepmc   +1 more source

Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials

open access: bronze, 2021
Natalie V. J. Aldhouse   +10 more
openalex   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

open access: yesMolecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir   +12 more
wiley   +1 more source

Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome. [PDF]

open access: yesGlomerular Dis
Salmon E   +15 more
europepmc   +1 more source

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. [PDF]

open access: yesNeuro Oncol, 2016
Blakeley JO   +5 more
europepmc   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force. [PDF]

open access: yesValue Health, 2017
Powers JH   +10 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy